Stock MPCI MEMPHIS PHARMACEUTICALS & CHEMICAL INDUSTRIES
Add to a list
To use this feature you must be a member
Log inSign up

Financials Memphis Pharmaceuticals & Chemical Industries

Equities

MPCI

EGS38351C010

Pharmaceuticals

End-of-day quote Egyptian Exchange
Other stock markets
 23:00:00 12/05/2024 BST 		5-day change 1st Jan Change
79.64 EGP -0.80% Intraday chart for Memphis Pharmaceuticals & Chemical Industries -16.39% +27.00%
02-14 Memphis Pharmaceuticals & Chemical Industries Reports Earnings Results for the Half Year Ended December 31, 2023 CI
2023 Memphis Pharmaceuticals & Chemical Industries Reports Earnings Results for the First Quarter Ended September 30, 2023 CI

Valuation

Fiscal Period: Giugno 2018 2019 2020 2021 2022 2023
Capitalization 1 63.73 49.61 86.74 150.2 77.85 174.2
Enterprise Value (EV) 1 53.57 3.009 47.38 103 -1.245 43.94
P/E ratio -1.36 x -1.95 x 4.98 x - 1.05 x 1.93 x
Yield - - - - - 6.46%
Capitalization / Revenue 0.19 x 0.14 x 0.18 x 0.29 x 0.14 x 0.26 x
EV / Revenue 0.16 x 0.01 x 0.1 x 0.2 x -0 x 0.07 x
EV / EBITDA -1.4 x -0.12 x 2.23 x 2.35 x -0.02 x 0.42 x
EV / FCF 2.14 x 0.06 x 1.43 x -72.5 x -0.53 x 0.99 x
FCF Yield 46.8% 1,699% 70.1% -1.38% -187% 101%
Price to Book -1.87 x -0.75 x -1.1 x - 2.12 x 1.66 x
Nbr of stocks (in thousands) 5,625 5,625 5,625 5,625 5,625 5,625
Reference price 2 11.33 8.820 15.42 26.70 13.84 30.96
Announcement Date 30/08/18 09/09/19 07/09/20 20/09/22 20/09/22 10/09/23
1EGP in Million2EGP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 339.6 363.1 488.4 518.1 551.3 663.8
EBITDA 1 -38.32 -25.79 21.29 43.88 76.68 103.7
EBIT 1 -48.05 -35.37 11.61 34.13 69.04 95.94
Operating Margin -14.15% -9.74% 2.38% 6.59% 12.52% 14.45%
Earnings before Tax (EBT) 1 -46.86 -25.97 15.8 41.65 78.32 110
Net income 1 -46.74 -25.38 17.41 41.81 74.09 90.44
Net margin -13.76% -6.99% 3.56% 8.07% 13.44% 13.62%
EPS 2 -8.309 -4.512 3.095 - 13.17 16.08
Free Cash Flow 1 25.06 51.12 33.2 -1.42 2.334 44.55
FCF margin 7.38% 14.08% 6.8% -0.27% 0.42% 6.71%
FCF Conversion (EBITDA) - - 155.95% - 3.04% 42.96%
FCF Conversion (Net income) - - 190.71% - 3.15% 49.26%
Dividend per Share - - - - - 2.000
Announcement Date 30/08/18 09/09/19 07/09/20 20/09/22 20/09/22 10/09/23
1EGP in Million2EGP
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 10.2 46.6 39.4 47.2 79.1 130
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 25.1 51.1 33.2 -1.42 2.33 44.5
ROE (net income / shareholders' equity) 1,473% 50.6% -24% -71.4% -9,615% 128%
ROA (Net income/ Total Assets) -8.51% -6.16% 2.02% 5.27% 8.7% 8.91%
Assets 1 549.3 412.1 863.7 792.6 851.6 1,015
Book Value Per Share 2 -6.070 -11.80 -14.00 - 6.510 18.70
Cash Flow per Share 2 8.540 8.570 8.310 - 14.90 25.50
Capex 1 0.38 0.99 0.8 2.07 12.9 11.5
Capex / Sales 0.11% 0.27% 0.16% 0.4% 2.34% 1.72%
Announcement Date 30/08/18 09/09/19 07/09/20 20/09/22 20/09/22 10/09/23
1EGP in Million2EGP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
MEMPHIS PHARMACEUTICALS & CHEMICAL INDUSTRIES Stock Memphis Pharmaceuticals & Chemical Industries
+27.00% 9.53M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+29.98% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.34% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.52% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.59% 329B
ABBVIE INC. Stock AbbVie Inc.
+4.07% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.21% 240B
NOVARTIS AG Stock Novartis AG
+9.66% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-6.83% 200B
AMGEN INC. Stock Amgen Inc.
+7.09% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MPCI Stock
  4. Financials Memphis Pharmaceuticals & Chemical Industries